Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 05.

374P - NX-019, a brain penetrant, mutation selective EGFR inhibitor with broad mutant EGFR activity

Date

03 Dec 2022

Session

Poster viewing 05.

Topics

Cancer Biology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Keith Wilson

Citation

Annals of Oncology (2022) 33 (suppl_9): S1560-S1597. 10.1016/annonc/annonc1134

Authors

K. Wilson, R. Dusek, G. Gammon

Author affiliations

  • Research And Development, Nalo Therapeutics, 94301 - Palo Alto/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 374P

Background

NX-019 is a potent, orally bioavailable and CNS penetrant EGFR inhibitor selectively targeting a broad range of EGFR mutations including common mutations (e.g., exon 19 deletions and exon 21 L858R), T790M, exon 20 insertions and other rare mutations. Therefore, NX-019 has the potential to treat patients with mutant EGFR tumors not adequately addressed by current therapies.

Methods

NX-019 was optimized for enhanced CNS penetration and potency against a broad range of EGFR mutations. Preclinical studies in multiple mutant EGFR disease models characterized the properties of NX-019 both in vitro and in vivo. These experiments included assessments of potency, efficacy, pharmacodynamic, pharmacokinetic and toxicity parameters.

Results

Preclinical in vitro and in vivo studies reveal that NX-019 has high potency across a broad range of mutant EGFR models indicating the potential of NX-019 to treat patients not currently covered or resistant to current EGFR TKI therapies. NX-019 is selective for mutant EGFR over wild-type EGFR and exhibits greater potency (7.3-200+ fold) in cell lines in cells with classic, exon20 insertion, and other rare mutations compared to cells expressing wildtype EGFR. This improved mutant selectivity should facilitate improved tolerability at higher dose levels and greater systemic exposures. Studies in preclinical animal models (mouse, rat, dog) did not show classical EGFR dermatological findings, in agreement with the improved selectivity profile of NX-019. Studies to measure the CNS efficacy of NX-019 in xenograft brain models (such as PC9 brain orthotopic model) show tumor regressions and prolonged PD effects (e.g., inhibition of phospho-EGFR). CNS exposure studies in multiple preclinical species shows a Kp,uu of approximately 1 indicating excellent CNS exposure.

Conclusions

Based on the preclinical profile of broad potency and mutant selectivity for EGFR mutations with excellent CNS exposure, NX-019 is entering a Phase I dose escalation and dose expansion trial in mutant EGFR selected patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Nalo Therapeutics.

Funding

Nalo Therapeutics.

Disclosure

K. Wilson: Financial Interests, Personal, Full or part-time Employment: Nalo Therapeutics; Financial Interests, Personal, Member of the Board of Directors: Nalo Therapeutics; Financial Interests, Personal, Stocks/Shares: Nalo Therapeutics; Financial Interests, Personal, Leadership Role: Nalo Therapeutics. R. Dusek: Financial Interests, Personal, Full or part-time Employment: Nalo Therapeutics; Financial Interests, Personal, Stocks/Shares: Nalo Therapeutics. G. Gammon: Financial Interests, Personal, Full or part-time Employment: Nalo Therapeutics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.